Brokerages Set TScan Therapeutics, Inc. (NASDAQ:TCRX) PT at $7.80

TScan Therapeutics, Inc. (NASDAQ:TCRX) has received an average rating of “Moderate Buy” from the six research firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $7.80.

Several equities research analysts recently issued reports on TCRX shares. Wall Street Zen upgraded TScan Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, July 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of TScan Therapeutics in a report on Wednesday, October 8th. Finally, Wedbush reiterated an “outperform” rating and issued a $7.00 target price on shares of TScan Therapeutics in a report on Tuesday, August 12th.

TScan Therapeutics Price Performance

TCRX stock opened at $2.48 on Friday. The company has a current ratio of 7.06, a quick ratio of 7.06 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $140.74 million, a PE ratio of -2.28 and a beta of 0.99. TScan Therapeutics has a 12-month low of $1.02 and a 12-month high of $6.22. The business’s fifty day moving average price is $1.89 and its 200 day moving average price is $1.66.

TScan Therapeutics (NASDAQ:TCRX) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.28). The firm had revenue of $3.08 million for the quarter, compared to the consensus estimate of $1.31 million. TScan Therapeutics had a negative return on equity of 63.33% and a negative net margin of 1,964.88%. On average, sell-side analysts anticipate that TScan Therapeutics will post -1.12 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Hsbc Holdings PLC purchased a new position in TScan Therapeutics in the first quarter valued at $49,000. Checkpoint Capital L.P. boosted its holdings in TScan Therapeutics by 14.9% in the first quarter. Checkpoint Capital L.P. now owns 2,017,650 shares of the company’s stock valued at $2,784,000 after purchasing an additional 261,663 shares during the period. BVF Inc. IL lifted its holdings in TScan Therapeutics by 63.6% during the 1st quarter. BVF Inc. IL now owns 4,889,474 shares of the company’s stock worth $6,747,000 after buying an additional 1,900,000 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in TScan Therapeutics by 6.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 170,349 shares of the company’s stock worth $235,000 after buying an additional 9,676 shares during the last quarter. Finally, Deutsche Bank AG lifted its holdings in TScan Therapeutics by 149.4% during the 1st quarter. Deutsche Bank AG now owns 52,559 shares of the company’s stock worth $73,000 after buying an additional 31,481 shares during the last quarter. 82.83% of the stock is currently owned by hedge funds and other institutional investors.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.